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Retinopathy of prematurity (ROP) is a vasoproliferative retinal 
disorder affecting premature, low-birth-weight infants and accounts 
for 10.2% of children admitted to schools for the blind in South 
Africa (SA).[1] The World Health Organization’s VISION 2020 
mission has recognised ROP as an important and preventable cause 
of childhood blindness.[2] Screening and appropriate treatment are 
imperative in this endeavour.
The findings of a multicentre trial of cryotherapy for ROP (CRYO-
ROP)[3] have shown the benefit of treatment with cryotherapy in 
reducing unfavourable visual outcome by 50% in infants at risk 
of proliferative retinopathy. Subsequently, the Early Treatment of 
ROP (ETROP) study[4] showed laser ablation to be superior to 
cryo therapy. Laser treatment remains the gold standard in treating 
threshold disease in ROP. The discovery of antivascular endothelial 
growth factor (anti-VEGF) in the treatment of colonic cancer[5] and 
its subsequent use in various proliferative vascular retinal conditions 
such as retinal vein occlusion[6] and diabetic retinopathy[7] have led 
to a paradigm shift in the management of these conditions. As an 
extension of this, anti-VEGF (bevacizumab) therapy has been used in 
treating ROP, initially as an adjunct to laser therapy and subsequently 
as primary treatment. Several case studies have reported favourable 
outcomes using bevacizumab therapy.[8-10]
In our hospital laser treatment, when indicated, is performed under 
general anaesthesia and although effective, it is time consuming and 
necessitates overnight observation in a high-care facility. Availability 
of beds in high care is often problematic. Intravitreal bevacizumab 
(IVB) can be administered under local anaesthesia, and high-care 
monitoring is not necessary.
Objective
To report our experience with the use of IVB injections as primary 
treatment of ROP.
Methods
This retrospective observational study analysed the efficacy of IVB 
in the treatment of ROP. The records of all patients with ROP who 
were treated with IVB injections over a 3-year period (2013 - 2015) at 
St John Eye Hospital, Johannesburg, SA, were reviewed. During that 
period, all infants were treated exclusively with IVB and none with 
laser photocoagulation. The hospital screens ~640 premature infants 
per year, using the screening guidelines recommended by the Royal 
College of Ophthalmology (UK) (Table 1). Indication for treatment is 
active disease as defined in the ETROP study[4] (Table 2).
After informed consent had been obtained from the parents, 
all patients were given an intravitreal injection of bevacizumab 
(Avastin; Genentech), a monoclonal anti-VEGF antibody, as an 
off-label but accepted treatment method. The drug was drawn 
from a standard multidose vial (100 mg/4 mL ampoule). Topical 
anaesthesia and povidone iodine drops were instilled into the eyes 
before the injection. No sedation was given. An anaesthetist is 
always available in theatre, but was not required. A dose of 0.625  mg 
(0.025  mL) bevacizumab was injected with a 30-gauge insulin 
syringe placed 1.5  mm from the limbus, under sterile conditions. 
None of the patients required high-care observation, and all were 
discharged, home or to the referring hospital where they were being 
treated for other comorbidities not related to the IVB procedure, 
several hours after the injection.
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All patients were seen 5 days after the injection, and the follow-up 
period was doubled at each consecutive visit until the retina was fully 
vascularised (or up to 60 weeks’ gestational age if the retinopathy 
responded favourably). If neovascularisation was still evident, laser 
treatment was given.
Outcome measures were complete regression of the proliferative 
phase and complete vascularisation of the retina.
A cost-effectiveness model was used to compare the cost of laser 
therapy with IVB. The cost was extrapolated from charges in a private 
hospital for the two procedures as well as current medical rates for 
follow-up visits. Public health sector costing was not possible. The 
preoperative preparation, intraoperative time and equipment used, 
postoperative need for high-care observation and length of follow-up 
were all calculated for the two groups.
Results were entered onto an Excel spreadsheet (2011, Microsoft, 
USA). Descriptive statistics were used for demographics.
Ethics approval was obtained from the Hospital Advisory Board 
(no reference number) and the Human Research Ethics Committee 
of the University of the Witwatersrand, Johannesburg (ref. no. 
M160306).
Results
Of 1 911 patients screened over the study period, 23 (1.2%) required 
treatment (Table 3). A total of 44 eyes received IVB injections, two 
patients requiring injections in only one eye. None of the infants 
required repeat injections for recurrences.
The mean birth weight was 1 074 g (range 810 - 1 480) and the 
mean gestational age 28 weeks (range 26 - 32). Only two infants 
had birth weights of >1 250 g. There were 13 males and 10 females.
Fourteen eyes had threshold disease and 28 had pre-threshold 
disease with plus disease (Table 3). Eighteen eyes had zone 1 disease 
and 26 had zone 2 disease requiring treatment.
The outcome of treatment was available for 22 patients (43 eyes); 
patient 10, with unilateral disease, defaulted (Table 3). Forty-one 
(95.3%) of 43 eyes showed complete regression or non-progression of 
ROP. Two patients (two eyes) showed progression, patient 11 in one 
eye and patient 5 with unilateral disease (Table 3). Both developed 
retinal detachment within 1 week after injection. None of the infants 
required laser intervention. No short-term adverse events were noted 
during a mean follow-up of 9 months (range 1 - 18).
When considering the economic aspects of treating patients with 
IVB compared with laser ablation, the cost of the injection was 
ZAR12 529.83 (with the potential maximum number of visits) and 
the cost of laser therapy was ZAR25 916.03 (Table 4). The difference 
was mainly due to theatre time and the need for overnight high-care 
monitoring associated with laser treatment. IVB-treated neonates 
require more follow-up visits.
Table 2. Indications to treat ROP (based on international classification of ROP)
Stage of ROP Zone Plus disease
CRYO-ROP criteria[3] (threshold 
disease)
3 (new vessels in 5 contiguous or 
8 non-contiguous clock hours)
1 or 2 Present
ETROP criteria[4] (type 1 ROP – 
pre-threshold disease)
Any 1 Present
3 1 Present or absent
2 or 3 2 Present












OS Response to IVB
Follow-up 
(mo) Vasularised
1 M 810 30 Zone 1 stage 3 
with plus
Zone 1 stage 3 
with plus
Yes 8 Yes, within 3 mo






Yes 6 Yes, within 3 mo
3 M 910 28 Zone 1 stage 3 
with plus
Zone 1 stage 3 
with plus
Yes 3 Yes, within 2 mo
4 F - 26 Zone 2 stage 3 
with plus
Zone 2 stage 3 
threshold with 
plus
Yes 6 Improved but still 




F 960 27 Zone 2 stage 1, 
no plus
Zone 1 stage 3 
with plus
No, OS total retinal 
detachment within  
1 wk (Rush disease)
6 No
Continued ... 
Table 1. Screening criteria for ROP
Who to screen:
All neonates born <32 weeks’ gestation
All preterm neonates weighing <1 500 g
When to screen:
 At 6 weeks’ chronological age or 31 - 33 weeks’ post-conceptual 
age (whichever comes later)
 If gestational age is inaccurate, neonates <28 weeks’ post-
conceptual age should be screened 6 weeks after birth and 
neonates >28 weeks’ post-conceptual age should be screened  
4 weeks after birth
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OS Response to IVB
Follow-up 
(mo) Vasularised
6 F 1 100 28 Zone 2 stage 3 
with plus
Zone 1 stage 3 
with plus
Yes 3 Yes, within 3 mo





Yes 4 Yes, within 4 mo
8 M 1 160 30 Zone 1 stage 3 
with plus
Zone 1 stage 3 
with plus
Yes 3 Yes, within 2 mo
9 F 840 28 Zone 2 stage 2 
with plus
Zone 1 stage 3 
threshold with 
plus
Yes 1 Lost to follow-up
10 
(unilateral)
M 885 29 Zone 2 
threshold with 
plus
Zone 2 stage 2, 
no plus
Given OD only, 
lost to follow-up
No Lost to follow-up
11 M 1 340 29 Zone 1 stage 3 
threshold with 
plus
Zone 2 stage 3 
with plus
OD yes/OS Rush 
disease stage 4b
1 OD yes
12 F 875 26 Zone 2 stage 3 
with plus
Zone 2 stage 3 
with plus
Yes 11 Yes, within 3 mo
13 M 1 390 32 Zone 1 stage 3 
with plus
Zone 1 stage 3 
with plus
Yes 1 No, lost to follow-
up
14 M 1 040 27 Zone 1 stage 3 
with plus
Zone 1 stage 3 
with plus
Yes 5 No, demarcation 
line peripheral 
zone 2
15 M 1 250 30 Zone 2 stage 3 
with plus
Zone 2 stage 1, 
no plus
Yes 2 Yes, within 2 mo
16 F 1 085 26 Zone 2 stage 3 
with plus
Zone 2 stage 3 
with plus
Yes 2 Yes, within 2 mo
17 F 1 195 29 Zone 2 stage 3 
threshold with 
plus
Zone 2 stage 3 
threshold with 
plus
Yes 11 Yes, within 3 mo
18 M 1 200 30 Zone 2 stage 3 
with plus
Zone 2 stage 3 
with plus
Yes 10 Yes, within 1 mo
19 M 840 26 Zone 2 stage 3 
with plus
Zone 2 stage 3 
with pre-plus
Yes 2 No, lost to follow-
up
20 F 825 27 Zone 2 stage 3 
with plus
Zone 2 stage 3 
with plus
Yes 2 Yes, within 1 mo
21 M 1 180 26 Zone 2 stage 3 
threshold with 
plus





Yes 1 Lost to follow-
up (followed up 
elsewhere)






Yes 18 Yes, within 4 mo
23 F 1 190 27 Zone 2 stage 3 
with plus
Zone 2 stage 3 
threshold with 
plus
Yes 8 No, not 
vascularised at last 
follow-up
M = male; F = female; OD = right eye; OS = left eye.
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Discussion
Our findings highlight several important issues regarding ROP in SA. 
Our study confirms previous findings that the incidence of severe 
ROP is low and that the current criteria of screening babies with a 
birth weight of <1 500 g are valid.[11] Notwithstanding the potential 
risk factors, screening heavier babies would place an unnecessary 
burden on the limited pool of ophthalmologists screening for ROP.
Laser ablation is still the mainstay of treatment. The ETROP study 
showed the advantage of treating high-risk infants earlier with laser, 
reducing the risk of an unfavourable outcome from 15.6% to 9% 
compared with the initial CRYO-ROP recommendations.[12] While 
laser therapy has been the treatment of choice for a number of years 
in our institution, every treatment event has a huge impact on our 
regular theatre list. A senior anaesthetist is needed, the procedure 
is time consuming, a special ambulance to transport the infant to 
a high-care facility is required, and high-care facility beds are not 
always available when they are needed.
Anti-VEGF injections have mainly been used for zone 1 disease, 
with good outcome. In a meta-analysis study, Alba et al.[13] concluded 
that an anti-VEGF agent was more beneficial than laser therapy in 
stage 3+ ROP in zone 1, but that there was no difference between the 
two in stage 3+ ROP in zone 2.[13] In a study of 23 patients, Isaac et 
al.[14] showed similar outcomes between laser therapy and anti-VEGF. 
The BEAT-ROP study was the first prospective randomised study to 
compare laser with IVB therapy. The findings showed a comparable 
outcome in the two groups with regard to efficacy and safety.[8]
We treated zone 1 and zone 2 type 1 disease with IVB, with 
favourable short-term outcomes. In our study 95.3% of patients 
showed complete regression with one injection. The BEAT-ROP 
study[8] showed a recurrence of 6% at a mean of 16 weeks after 
the injection. In a Canadian study on involutional pattern of ROP 
following IVB injections, Isaac et al.[15] reported recurrence in 
61% of their patients. However, recurrences were stage 1 or 2 and 
none required retreatment. We did not observe any recurrence 
of the disease in our patients. The majority of our patients had 
complete vascularisation, only two patients showing incomplete 
vascularisation in zone 3 even after 6 months of follow-up. The two 
eyes with unfavourable results had aggressive posterior disease that 
progressed within 1 week of the injection.
The safety profile of anti-VEGF use in ROP is still of concern. 
IVB has been reported to suppress serum levels of VEGF for up to 
2 months after the injection.[16] In another study, Menke et al.[17] 
attributed upper respiratory infection in one patient as a possible 
complication. The BEAT-ROP study established the safety profile 
of IVB, finding no systemic side-effects at the 3-year follow up. 
However, long-term side-effects have not been established. None 
of our patients developed short-term complications attributed to 
IVB.
There has been no report on the logistical advantage of IVB 
therapy over laser, in terms of resources or cost. Our study shows a 
clear benefit of IVB over laser, the cost of laser therapy being twice as 
high, although follow-up visits are more frequent with IVB.
Study limitations
Limitations of the study are its retrospective nature and the lack of 
fluorescein angiography to document full vascularisation, as well as 
loss to follow-up of 2 patients.
Conclusion
Our study demonstrates that the use of IVB as an anti-VEGF agent 
in the treatment of ROP is effective and safe. In resource-limited 
centres, the use of IVB as first-line therapy in all type 1 disease may 
be more practical than laser therapy with regard to both clinical 
management and the economic burden of treatment.
1. O’Sullivan J, Gilbert C, Foster A. The causes of childhood blindness in South Africa. S Afr Med J 
1997;87(12):1691-1695.
2. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020 – the right to sight. Bull 
World Health Organ 2001;79(3):227-232.
3. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for 
retinopathy of prematurity: Natural history ROP: Ocular outcome at 5(1/2) years in premature infants 
with birth weights less than 1251 g. Arch Ophthalmol 2002;120(5):595-599.
4. Early Treatment for Retinopathy of Prematurity Cooperative Group, Good WV, Hardy RJ, Dobson 
V, et al. Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch 
Ophthalmol 2010;128(6):663-671. http://dx.doi.org/10.1001/archophthalmol.2010.34
5. Ferrara N, Hillan KJ, Gerber H-P, Novotny W. Discovery and development of bevacizumab, an 
anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3(5):391-400. http://dx.doi.
org/10.1038/nrd1381
6. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central 
retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 
2010;117(6):1124-1133. http://dx.doi.org/10.1016/j.ophtha.2010.02.022
7. Jampol LM, Glassman AR, Bressler NM. Comparative effectiveness trial for diabetic macular edema: 
Three comparisons for the price of 1 study from the Diabetic Retinopathy Clinical Research Network. 
JAMA Ophthalmol 2015;133(9):983-984. http://dx.doi.org/10.1001/jamaophthalmol.2015.1880
8. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of 
intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364(7):603-
615. http://dx.doi.org/10.1056/NEJMoa1007374
9. Bancalari MA, Schade YR, Peña ZR, Pavez PN. [Intravitreal bevacizumab as single drug therapy for 
retinopathy of prematurity in 12 patients.] Arch Argent Pediatr 2014;112(2):160-163. http://dx.doi.
org/10.5546/aap.2014.160
10. Baumal CR, Goldberg RA, Fein JG. Primary intravitreal ranibizumab for high-risk retinopathy 
of prematurity. Ophthalmic Surg Lasers Imaging Retina 2015;46(4):432-438. http://dx.doi.
org/10.3928/23258160-20150422-5
11. Mayet I, Cockinos C. Retinopathy of prematurity in South Africans at a tertiary hospital: A pro-
spective study. Eye (Lond) 2006;20(1):29-31. http://dx.doi.org/10.1038/sj.eye.6701779
12. Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the 
Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol 
Soc 2004;102:233-250.
13. Alba LE, Zaldua RA, Masini RA. [Off-label use of intravitreal bevacizumab for severe retinopathy of 
prematurity.] Arch Soc Esp Oftalmol 2015;90(2):81-86. http://dx.doi.org/10.1016/j.oftal.2014.09.011
14. Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with bevacizumab 
versus laser. J AAPOS 2015;19(2):140-144. http://dx.doi.org/10.1016/j.jaapos.2015.01.009
15. Isaac M, Tehrani N, Mireskandari K. Involution patterns of retinopathy of prematurity after treatment 
with intravitreal bevacizumab: Implications for follow-up. Eye (Lond) 2016;30(3):333-341. http://
dx.doi.org/10.1038/eye.2015.289
16. Wu W-C, Lien R, Liao P-J, et al. Serum levels of vascular endothelial growth factor and related 
factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 
2015;133(4):391-397. http://dx.doi.org/10.1001/jamaophthalmol.2014.5373
17. Menke MN, Framme C, Nelle M, et al. Intravitreal ranibizumab monotherapy to treat retinopathy 
of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol 2015;15:20. http://dx.doi.
org/10.1186/s12886-015-0001-7
Accepted 20 September 2016.
Table 4. Cost analysis comparing laser therapy with  
IVB (ZAR)
Laser IVB
Theatre fee 16 182.00 (1.5 h) 1 798.00 (10 min)
Medical stock 7 281.90 1 231.83
Neonatal high care 7 452.13  -
Laser hire fee 1 500.00  -
Cost of bevacizumab - 1 000.00
Follow-up visits 
(ZAR700.00/visit)
3 500.00 (average 
5 visits)
8 400.00 (average 
12 visits)
Total 25 916.03 12 529.83
